This site is intended for healthcare professionals
Small cell lung cancer, light micrograph

Video series: Transforming SCLC care

Supported by Amgen
Last updated: 18th Aug 2026
Published: 18th Aug 2026

Jacob Sands and Eric Singhi discuss ES-SCLC management

EBAC accredited; 0.33 CME credit

Gain insights into the management of extensive-stage small-cell lung cancer (ES-SCLC) with Jacob Sands (Harvard Medical School, Boston, Massachusetts, USA) and Eric Singhi (The University of Texas MD Anderson Cancer Center, Houston, USA). In this accredited video, they discuss later-line management strategies, emerging evidence, and how clinical data can be applied in practice. Earn 0.33 CME credit upon successful completion.

How much do you know about later-line management of ES-SCLC?

Answer this question to find out. We’ll ask it again after you’ve watched the video to see what you recall.

1. A patient with ES-SCLC experiences disease progression following first-line platinum-based chemo-immunotherapy and remains eligible for further treatment. Which approach is most consistent with contemporary management recommendations?

Thumbnail for Youtube Later-Line management of ES-SCLC

Watch Episode 1: Later-line management of ES-SCLC: Applying evidence to practice.

 

This video is part of an accredited series for oncologists, including thoracic oncologists, involved in the care of people with ES-SCLC.

A total of 1 CME credit is available across all three episodes, with each episode worth 0.33 CME credit. To claim credit for an episode, complete the associated knowledge quiz and evaluation form after viewing the video.

Available now

  • Episode 1 – Later-line management of ES-SCLC: Applying evidence to practice

Coming soon

  • Episode 2 – Supporting patients every step of the way (Available in October)
  • Episode 3 – What are the current treatment options for people with ES-SCLC? (Available in November)


How to claim your CME credit

  1. Watch the video on our YouTube channel
  2. At the end of the video, make a note of the CME code
  3. Use the link in the video description to return to Medthority
  4. Complete the knowledge quiz and evaluation form to claim your CME certificate

 

Meet the experts

Jacob Sands, MDJacob Sands, MD

Jacob Sands is Associate Chief of the Lowe Center for Thoracic Oncology, Boston, Massachusetts, USA, and Assistant Professor of Medicine at Harvard Medical School. He leads the small-cell lung cancer clinical and research program and has authored numerous publications in non–small-cell lung cancer (NSCLC) and SCLC. Sands serves on the National Comprehensive Cancer Network (NCCN) Small Cell Lung Cancer and Lung Screening Guidelines Committees and is co-founder and President of the Rescue Lung Society, a nonprofit dedicated to advancing lung cancer screening and early detection.

Disclosures: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, GSK, Jazz Pharmaceuticals, Lilly, Merck, Novartis, Pfizer, and Sanofi.

 

Eric Singhi, MDEric Singhi, MD

Eric Singhi is Assistant Professor and Thoracic Medical Oncologist at The University of Texas MD Anderson Cancer Center, Houston, USA. He serves as medical oncology lead for the Young-Onset Lung Cancer Program, Director of Thoracic Research for the MD Anderson Cancer Network, and is a member of the American Society of Clinical Oncology (ASCO) NSCLC Guidelines Committee and International Association for the Study of Lung Cancer (IASLC) Communications Committee.

Disclosures: AstraZeneca, Novocure, Amgen, Janssen, Regeneron, Bristol Myers Squibb, Bayer, Lilly, Boehringer Ingelheim, Caris Life Sciences, AbbVie, GSK, Rexanna's Foundation for Fighting Lung Cancer, Roche, Sandoz, Summit Therapeutics, Nuvation Bio, Nuvalent, and EMD Serono.

 

MORE SCLC RESOURCES

Welcome:

Developed independently by EPG Health, which received educational funding from Amgen awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.

This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0:33 hours of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the European Board for Accreditation of Continuing Education for Health Professionals, Royal College MOC Section 1 credits are deemed to be substantively equivalent to EBAC CPD credits.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).